[Pembrolizumab as neoadjuvant treatment of early triple-negative breast cancer]
- PMID: 32561940
- DOI: 10.1007/s00066-020-01641-9
[Pembrolizumab as neoadjuvant treatment of early triple-negative breast cancer]
Comment on
-
Pembrolizumab for Early Triple-Negative Breast Cancer.N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549. N Engl J Med. 2020. PMID: 32101663 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical